Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Desmoid-type fibromatosis: Current therapeutic strategies and future perspectives.
Ibrahim R, Assi T, Khoury R, Ngo C, Faron M, Verret B, Lévy A, Honoré C, Hénon C, Le Péchoux C, Bahleda R, Le Cesne A. Ibrahim R, et al. Among authors: bahleda r. Cancer Treat Rev. 2024 Feb;123:102675. doi: 10.1016/j.ctrv.2023.102675. Epub 2023 Dec 25. Cancer Treat Rev. 2024. PMID: 38159438 Review.
Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate.
Pautier P, Locher C, Robert C, Deroussent A, Flament C, Le Cesne A, Rey A, Bahleda R, Ribrag V, Soria JC, Vassal G, Eggermont A, Zitvogel L, Chaput N, Paci A. Pautier P, et al. Among authors: bahleda r. Oncoimmunology. 2013 Feb 1;2(2):e23079. doi: 10.4161/onci.23079. Oncoimmunology. 2013. PMID: 23525192 Free PMC article.
A Comprehensive Review on the Role of Lurbinectedin in Soft Tissue Sarcomas.
Khoury R, Assi T, Ibrahim R, Ibrahim T, Verret B, Henon C, Bahleda R, Le Cesne A. Khoury R, et al. Among authors: bahleda r. Curr Treat Options Oncol. 2024 Feb;25(2):176-190. doi: 10.1007/s11864-024-01178-4. Epub 2024 Feb 7. Curr Treat Options Oncol. 2024. PMID: 38324075 Review.
Profile and outcome of cancer patients enrolled in contemporary phase I trials.
Alouani E, Gazzah A, Mercier S, Bahleda R, Hollebecque A, Michot JM, Baldini C, Ammari S, Champiat S, Marabelle A, Postel-Vinay S, Ribrag V, Loriot Y, Aix SP, Mahjoubi L. Alouani E, et al. Among authors: bahleda r. Eur J Cancer. 2023 Jul;188:1-7. doi: 10.1016/j.ejca.2023.04.006. Epub 2023 Apr 20. Eur J Cancer. 2023. PMID: 37178645 Clinical Trial.
Pemetrexed-induced pneumonitis: a case report.
Loriot Y, Ferte C, Gomez-Roca C, Moldovan C, Bahleda R, Wislez M, Cadranel J, Soria JC. Loriot Y, et al. Among authors: bahleda r. Clin Lung Cancer. 2009 Sep;10(5):364-6. doi: 10.3816/CLC.2009.n.050. Clin Lung Cancer. 2009. PMID: 19808196
Tumour growth rates and RECIST criteria in early drug development.
Gomez-Roca C, Koscielny S, Ribrag V, Dromain C, Marzouk I, Bidault F, Bahleda R, Ferté C, Massard C, Soria JC. Gomez-Roca C, et al. Among authors: bahleda r. Eur J Cancer. 2011 Nov;47(17):2512-6. doi: 10.1016/j.ejca.2011.06.012. Epub 2011 Jul 15. Eur J Cancer. 2011. PMID: 21763126
116 results